LDN-192960 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of the enzyme PI3K (phosphoinositide 3-kinase), which plays a crucial role in cell growth, proliferation, and survival. By inhibiting PI3K, LDN-192960 can disrupt signaling pathways that are often dysregulated in cancer cells, potentially leading to the suppression of tumor growth and metastasis. Research is focused on its use in treating cancers where PI3K signaling is abnormally active, such as breast, ovarian, and prostate cancers. Additionally, its role in combination therapies with other anticancer agents is being explored to enhance treatment efficacy and overcome drug resistance.